Immunology & Inflammation
One of the more surprising ideas in psychedelic science is that these drugs might be powerful anti-inflammatories, acting on the same serotonin 2A receptor that produces their psychological effects, and that some of their benefit for depression might come from calming inflammation rather than from the experience at all. It is a genuinely interesting hypothesis, and it is also one of the field’s most preclinical. The striking effects come almost entirely from mouse, rat and cell studies, and the molecule that carries the headline mechanism is a research chemical, not a medicine. In humans the picture is thin and mixed: small, short-lived cytokine changes that sometimes appear and sometimes do not, one study finding the classic psychedelics do nothing to immune cells directly, and no completed trial in any actual inflammatory disease. This page lays out the exciting mechanism and the sober reality of how little of it has been shown in people.
Data updated
Key Insights
- 1
This is a mechanism theme page, not a condition or a treatment. It covers the idea that psychedelics affect the immune system and inflammation, including the striking proposal that they could be a new class of anti-inflammatory drug.
- 2
The core mechanism is real but preclinical. Activating the serotonin 2A receptor has powerful anti-inflammatory effects in animal models, most famously where a psychedelic compound prevented asthma in mice, and intriguingly, the anti-inflammatory potency does not track the hallucinogenic potency, raising the prospect of a non-tripping anti-inflammatory.
- 3
The molecule carrying the headline is not a medicine. Most of the dramatic anti-inflammatory data come from a research chemical (DOI), not from psilocybin or LSD in patients, so the leap from "5-HT2A activation is anti-inflammatory in mice" to "psychedelics treat inflammatory disease in people" is an inference, not a finding.
- 4
In humans the evidence is thin, small and inconsistent. Some studies find brief dips in inflammatory markers after dosing; others find no change; one direct test found the classic psychedelics do nothing to human immune cells at all. The changes that do appear are confounded by the stress and cortisol rise that dosing itself causes.
- 5
There are essentially no human trials in real inflammatory disease. The inflammation-and-depression link is a live hypothesis, but in the one positive human study the inflammatory marker fell without predicting who got better, so even there, inflammation is not clearly the mechanism.
By the numbers
- 14
- Trials tracked
- 101
- Papers tracked
- 551
- Trial participants
as of June 2026
as of June 2026
as of June 2026
About Immunology & Inflammation
Immunology and inflammation is not a condition or a treatment; it is a mechanism, and a surprising one. Alongside their effects on mood and perception, psychedelics appear to influence the immune system, and a striking hypothesis has grown up around this: that activating the serotonin 2A receptor, the same target responsible for the psychedelic experience, is powerfully anti-inflammatory, and that psychedelics might therefore be useful not just in psychiatry but in inflammatory and autoimmune disease, and perhaps that some of their antidepressant effect works by calming inflammation rather than through the experience itself.
It is a genuinely exciting idea, and this page treats it as exactly that, an idea, because that is overwhelmingly what the evidence supports. This is one of the most preclinical topics in the whole field. The dramatic results come from mice, rats and cells in dishes; the human data are sparse, small and inconsistent; and a great deal of the apparent weight of evidence comes from review articles that recycle the same handful of animal studies. Separating the compelling mechanism from the thin human reality is the entire task here.
The single most important idea to carry through this page is the gap between an effect in a mouse and a treatment in a person. The anti-inflammatory mechanism is real in animals, and the chemistry of separating it from the trip is a serious research direction. But almost none of it has been demonstrated in humans, the molecule carrying the headline mechanism is not even a clinical drug, and the proposed link to depression remains a hypothesis. Read this page for the promise of the mechanism, and the discipline of how little of it has yet been shown where it matters: in people.
Approach & Methods
Because there is no condition here, the relevant "evidence" is mechanistic, and its backbone is animal pharmacology. The foundational result is that a psychedelic compound, given by inhalation, prevented the key features of allergic asthma in mice[1], an unusually clean and dramatic anti-inflammatory effect. A follow-up went further and found something genuinely important: across more than twenty 5-HT2A agonists, anti-inflammatory potency did not correlate with hallucinogenic potency[2], which means, in principle, that the anti-inflammatory effect could be engineered without the trip, a direct link to the non-hallucinogenic drug-design work elsewhere on this site.
The honest qualifier is that this entire backbone is preclinical, and the molecule that carries it, a research chemical called DOI, is not a medicine and has no clinical track record in people. When researchers have looked directly at whether the actual psychedelics do anything to human immune cells, the answer has sometimes been no: one study found that LSD, psilocin, DMT and mescaline had no relevant direct effect on human T cells and monocytes[3]. So the "standard" understanding here is a strong animal mechanism, a promising but unproven idea about non-hallucinogenic anti-inflammatories, and a real possibility that the headline effect does not straightforwardly transfer to the drugs people actually take.
This report summarises what Blossom’s database shows about psychedelics, the immune system and inflammation. It is worth being clear what kind of page this is. It is not a condition page and not a treatment. It is about a mechanism, and a striking hypothesis built on it: that psychedelics are anti-inflammatory, and that this might matter both for inflammatory disease and for how they treat depression. The hypothesis is genuinely interesting. It is also, more than almost any other topic on this site, a story told from animals and cells rather than from people.
A note before the evidence
This page is a research summary, not medical advice, and nothing here is a recommendation to take psychedelics, least of all for an inflammatory or autoimmune condition. The anti-inflammatory findings described below come overwhelmingly from laboratory models, not from treated patients, and the human evidence is thin and inconsistent. Read this as an account of a promising mechanism, not of a demonstrated therapy.
The exciting mechanism, and where it comes from
The idea starts with a clean and dramatic result. A psychedelic compound, inhaled, prevented the major features of allergic asthma in mice[1], acting through the serotonin 2A receptor, the same receptor responsible for the psychedelic experience. A follow-up added a genuinely exciting twist: testing more than twenty related compounds, researchers found that how strongly a molecule fought inflammation had nothing to do with how strongly it caused hallucinations[2]. That dissociation is the seed of a real ambition, an anti-inflammatory drug that hits this receptor without producing a trip.
There is a second, separate mechanism too, centred on DMT and the sigma-1 receptor. In human immune cells in a dish, DMT and 5-MeO-DMT calmed inflammatory signalling and boosted an anti-inflammatory cytokine[3], and the same pathway protected human nerve cells from oxygen starvation[4] and limited brain damage in rats[5]. Taken together, these are two plausible, well-described ways psychedelics could be anti-inflammatory. The catch is in the phrase that keeps recurring: in mice, in rats, in a dish.
The molecule that carries the story is not a medicine
The most important caveat about the headline mechanism is easy to miss. The compound at the centre of the asthma work, and much of the 5-HT2A anti-inflammatory literature, is a research chemical called DOI. It is a superb laboratory tool, but it is not a clinical drug, has never been developed as a human medicine, and is not what anyone takes. So the chain of reasoning from "5-HT2A activation is powerfully anti-inflammatory in mice" to "psilocybin or LSD will treat inflammatory disease in people" passes through a molecule that is neither psilocybin nor LSD nor a medicine. That is an inference, and a long one, not a demonstrated result.
The point is sharpened by what happens when researchers test the actual psychedelics directly on human immune cells. In at least one careful study, LSD, psilocin, DMT and mescaline produced no relevant direct immune effect at all[6]. That negative result sits awkwardly with the enthusiastic reviews, and an honest account has to give it weight: the drugs people actually use may simply not do, in human immune cells, what the research-chemical and animal literature suggests they should.
In people: small, brief, and contradictory
Where psychedelics have been given to humans and their inflammatory markers measured, the results are a study in inconsistency. One trial found psilocybin acutely lowered the inflammatory cytokine TNF-alpha[7]; another, also single-dose, found no change in any inflammatory marker[8]. For 5-MeO-DMT, a small study found a drop in salivary IL-6[9], and an MDMA-therapy pilot found small, mixed-direction changes[10]. This is not the footprint of a strong, reliable anti-inflammatory effect; it is the pattern you see when an effect is weak, variable, or not really there.
A specific confound makes even the positive findings hard to interpret. A full psychedelic dose is a major physiological event that sharply raises cortisol, the stress hormone, and cortisol itself shifts inflammatory markers. So a brief change in a cytokine an hour after dosing may be the body’s stress response to an intense experience rather than a direct anti-inflammatory action of the drug. Until studies are designed to separate the two, the human cytokine data cannot bear much weight in either direction.
The inflammation-and-depression idea
The most clinically appealing version of this topic is the proposal that psychedelics ease depression partly by reducing inflammation, since depression is associated with raised inflammatory markers. The best human evidence is the ayahuasca depression trial, in which C-reactive protein fell with treatment and the fall tracked the improvement in mood[11]. That is the single most supportive human result on the page.
And yet the same study undercuts the strong version of the claim. A second inflammatory marker did not move, and, decisively, the inflammatory markers did not predict who actually got better. If inflammation were the mechanism, you would expect the people whose inflammation fell most to improve most; that link was not established. The honest reading is that inflammation may fall alongside antidepressant recovery without driving it, a correlation, not a demonstrated cause. The inflammation-and-depression hypothesis remains live and worth testing, but it has not been shown to be true in people.
Reading this honestly
So how should you read the immunology story? As one of the field’s most exciting mechanisms and one of its least proven applications. The animal and cell pharmacology is real: activating the serotonin 2A receptor is powerfully anti-inflammatory in models, DMT has a credible sigma-1 mechanism, and the discovery that anti-inflammatory and hallucinogenic effects can be separated is genuinely important, pointing toward a possible non-tripping anti-inflammatory drug. But almost none of this has been shown where it would matter. The headline mechanism rides on a research chemical that is not a medicine; a direct test on human immune cells found nothing; the human cytokine studies are small, brief, contradictory and confounded by the stress of dosing; the one positive human result did not establish inflammation as the cause of benefit; and there is not a single completed trial in any actual inflammatory disease. The most useful thing this literature offers an honest reader is a clear separation between a compelling laboratory hypothesis and a clinical claim that has not been earned. The mechanism deserves serious testing. It does not yet deserve to be called a treatment.
Acute Effect Characterisation
Acute drug effects and evidence levels observed in Immunology & Inflammation research — characterisation, not therapeutic efficacy.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| DMT This matrix characterises the prominence of each compound’s immune SIGNAL in the evidence (mostly preclinical), not therapeutic efficacy. DMT has the most developed anti-inflammatory mechanism via the sigma-1 receptor, but it is entirely preclinical: suppression of inflammatory cytokines in human cells in a dish and neuroprotection in rat ischaemia. No human inflammatory-disease endpoints exist. | Medium | Very Low | Moderate |
| Ayahuasca Preclinical/signal-only immune characterisation, not efficacy. Ayahuasca is the only compound with a positive HUMAN inflammatory readout: C-reactive protein fell in a depression trial. But interleukin-6 was unchanged and the marker did not predict who improved, so inflammation is not clearly the mechanism. | Small | Low | Low |
| Psilocybin Preclinical/signal-only immune characterisation, not efficacy. Human cytokine data are conflicting: one study found an acute drop in TNF-alpha (and lower IL-6/CRP a week later), another found no change in any inflammatory marker. The changes are small, transient and confounded by the cortisol rise from dosing. | Small | Low | Low |
| 5-MeO-DMT Preclinical/signal-only immune characterisation, not efficacy. A sigma-1 anti-inflammatory signal in cells (shared with DMT) plus a single small human study (n=11) showing lower salivary IL-6 after dosing, alongside a sharp cortisol rise that itself shifts cytokines. Very thin. | Small | Very Low | Low |
| LSD Preclinical/signal-only immune characterisation, not efficacy. LSD appears mainly in the anti-inflammatory review literature by association, but a direct test on human immune cells found no immunomodulation, and there is no dedicated human inflammatory data for it. Included to mark the honest negative. | None | Very Low | Low |
DMT and Immunology & Inflammation
DMT carries the most developed immune mechanism in the field, and it is a different one from the 5-HT2A asthma story: it acts on the sigma-1 receptor, found on immune and nerve cells. In human dendritic cells in a dish, DMT and 5-MeO-DMT suppressed pro-inflammatory signals and boosted the anti-inflammatory cytokine IL-10, specifically through that receptor[1]. The same pathway underlies its neuroprotective claims: DMT protected human nerve and microglial cells against oxygen deprivation[2] and limited neurodegeneration in the ischaemic rat brain[3].
This is real, careful pharmacology, and it is also entirely preclinical. Every one of these findings is in cells or in rats; none involves a human being with an inflammatory or neurological disease. The honest reading is that DMT has the most plausible and best-characterised immune mechanism of any psychedelic, and that this tells us about the molecule, not yet about any treatment. The distance between "suppresses cytokines in a dish" and "helps a patient" is exactly the distance this whole page is about.
Ayahuasca and Immunology & Inflammation
Ayahuasca is the one compound with a genuinely positive human inflammatory result, which makes it the most important and the most instructive case. In a depression trial, C-reactive protein, a standard inflammation marker, fell after ayahuasca but not placebo, and the size of the drop tracked the improvement in mood[1]. Taken alone, that looks like support for the whole "psychedelics treat depression by reducing inflammation" hypothesis.
But the same study is a lesson in not over-reading. Interleukin-6, another key inflammatory marker, did not change, and crucially the inflammatory biomarkers did not predict who actually responded to treatment. So even in the best human case, the evidence is consistent with inflammation falling alongside recovery without being the cause of it, the classic correlation-is-not-mechanism trap. The defensible statement is that ayahuasca can lower an inflammatory marker in people, and that this is intriguing rather than conclusive evidence that inflammation is how it works.
Psilocybin and Immunology & Inflammation
Psilocybin is where the human inconsistency is clearest. One study in healthy volunteers found that it acutely lowered the inflammatory cytokine TNF-alpha, with IL-6 and CRP modestly lower a week later[1], which fits the anti-inflammatory story. But another single-dose study found no significant change in any inflammatory marker at all[2]. Two reasonable studies, opposite conclusions, which is the signature of a weak and unsettled effect rather than a robust one.
There is also a confound that haunts all of these acute human measurements. A psychedelic dose is a major physiological event that sharply raises cortisol, the body’s stress hormone, and cortisol itself moves inflammatory markers around. So a brief dip in a cytokine after dosing may reflect the stress response to the experience rather than a specific anti-inflammatory action of the drug. Until studies can separate those two, the honest position on psilocybin and inflammation is that the human signal is small, inconsistent, and not yet clearly attributable to the drug at all.
Research Outlook
The most genuinely promising direction here is not a treatment but a piece of chemistry. The finding that anti-inflammatory potency can be separated from hallucinogenic potency[1] is the seed of a real idea: a non-hallucinogenic 5-HT2A drug that delivers the anti-inflammatory benefit without the psychedelic experience, which would sidestep all the access and supervision problems of psychedelic therapy. That is an active and serious drug-discovery avenue, though it is years from the clinic and belongs as much to medicinal chemistry as to immunology.
For the psychedelics people actually use, the priority is simply human evidence, of which there is almost none. Encouragingly, registered trials are now adding immune and inflammatory markers as endpoints rather than afterthoughts, and the inflammation-and-depression hypothesis is being tested directly[2]. But the field has to confront its own negatives, including the study finding no direct immune effect of the classic psychedelics on human cells[3], and the small, mixed-direction results of early human work such as an MDMA-therapy pilot[4]. The honest outlook is a compelling preclinical mechanism, a promising non-hallucinogenic chemistry spin-off, and a near-total absence of the human disease evidence that would turn either into a therapy.
Industrial Landscape
The immunology angle is driven mainly by academic pharmacology labs, where the foundational anti-inflammatory work originated[1], and by a body of review articles that have done a great deal to popularise the idea. That review literature is worth naming honestly: a large share of this topic’s apparent evidence base consists of enthusiastic syntheses[2] that repeatedly cite the same small set of preclinical primary studies[3], which can create an impression of evidentiary depth that the underlying human data do not support. Commercially, the most credible interest is in the non-hallucinogenic anti-inflammatory chemistry, where the value would lie in a patentable, trip-free molecule.
For an honest broker, immunology and inflammation is the clearest case on the site of a genuinely exciting mechanism getting ahead of its evidence. The animal pharmacology is real and the non-hallucinogenic idea is clever and worth pursuing. But the field has, in effect, told an "anti-inflammatory" story largely from mice, a research chemical, and review papers, while the human evidence remains a handful of small, conflicting, confounded studies, one outright negative, and zero completed trials in any actual inflammatory disease. The responsible posture credits the mechanism as a hypothesis worth serious testing, foregrounds the foundational reviews[4] as hypotheses rather than conclusions, and keeps the language precise: psychedelics show an anti-inflammatory signal in the laboratory, and have not been shown to treat inflammation in people.
Quick Indicators
Organisations
Search →Restart Life Sciences
Canadian biotech (formerly Nova Mentis Life Science, renamed November 2024) developing psilocybin therapy for Fragile X Syndrome and autism spectrum disorder. Lead candidate NM-1001 received Health Canada authorisation for a Phase IIA clinical trial, making it one of the few psilocybin programmes targeting neurodevelopmental conditions.
National Institute of Mental Health (NIMH)
U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
Imperial College London
The Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
University of Basel
The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.
University of Ottowa
The University of Ottawa launched a groundbreaking one-year MA in Psychedelics and Consciousness Studies in 2024, jointly offered by the Faculty of Social Sciences and Faculty of Arts under co-directors Dr. Monnica Williams and Dr. Anne Vallely. The program builds on earlier microprograms in Psychedelic Science and Psychedelics & Spirituality Studies established since 2020, training licensed professionals, clergy, and researchers in therapeutic, spiritual, and academic dimensions of psychedelics.
King's College London
The Centre for Mental Health Research and Innovation and the Psychoactive Trials Group are actively conducting clinical trials with various psychedelic compounds to develop new care models for treatment-resistant depression, PTSD, and anorexia nervosa.
Johns Hopkins University
The Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
Yale University
In 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
Oregon Health & Science University
Researchers at the Social Neuroscience and Psychotherapy (SNAP) Lab at OHSU are investigating the therapeutic potential of psychedelics. Assistant Professor of Psychiatry, Dr Chris Stauffer, is the current director of the lab. SNAP Lab aims to maximize the benefits of therapeutic alliance and psychotherapy through the adjunct use of social psychopharmacology, such as oxytocin, MDMA, and psilocybin. Dr Stauffer led a research team from OHSU in a clinical trial exploring the effects of psilocybin in methamphetamine use disorder. With Oregon becoming the first state to legalize psilocybin-assisted therapy, more research is taking place at OHSU.
Federal University of São Paulo (UNIFESP)
The Federal University of São Paulo (UNIFESP) is a public federal research university based in the state of São Paulo, Brazil, with multiple campuses and a strong reputation in health sciences and related programs.
Federal University of Rio Grande do Norte (UFRN)
Federal University of Rio Grande do Norte is a public research university in Brazil with active neuroscience and mental health research programmes, including work linked to psychedelic science through affiliated institutes.
People
Search →Attila Szabo
Researcher in psychoneuroimmunology and psychedelic science; affiliated with the University of Oslo
He is a notable contributor to psychedelic immunology research, including widely cited work on DMT, 5-MeO-DMT, psilocybin, and immune modulation.
Kayla Teopiz
Researcher in psychiatry and ketamine/psychedelic medicine research; likely affiliated with the University of Toronto/Trillium Health Partners research network
Teopiz coauthors multiple systematic reviews and clinical studies on ketamine, esketamine, and psilocybin in depression and suicidality, helping synthesize the evidence base for psychedelic and glutamatergic treatments in psychiatry.
Michiel Van Elk
Associate Professor of Cognitive Psychology at Leiden University
Michiel van Elk is a prominent psychedelic science researcher known for rigorous, skeptical work on psilocybin, microdosing, expectancy effects, and the psychological mechanisms and risks of psychedelic experiences.
Joshua Di Vincenzo
MSc researcher / clinical research staff member at the University Health Network and University of Toronto
He coauthors multiple systematic reviews and real-world studies on ketamine for treatment-resistant depression, making him a visible contributor to the evidence base on psychedelic-adjacent psychiatric therapeutics.
Valerie Bonnelle
Scientific Assistant to the Director at the Beckley Foundation
She is a researcher coordinating psychedelic studies on microdosing, pain, autonomic physiology, and peak experiences, contributing to the clinical and mechanistic understanding of psychedelic effects.
Bing Cao
PhD researcher at the Key Laboratory of Cognition and Personality, Faculty of Psychology, Southwest University
He is a recurring coauthor on multiple ketamine and psychedelic-adjacent systematic reviews and mechanistic studies, making him a visible contributor to contemporary rapid-acting antidepressant research.
Marcelo Falchi
Psychiatrist, Professor of Medicine at the Federal University of Rio Grande do Norte (UFRN), and Medical Director at the Center for Advanced Psychedelic Medicine (CAMP)
He is a Brazilian psychiatrist and psychedelic-science researcher involved in pioneering LSD and DMT clinical studies, including work on cognition, creativity, language, and inhaled DMT safety.
Mark Andrew Frye
Chair, Department of Psychiatry and Psychology, Mayo Clinic (Rochester, Minnesota)
He is a leading mood-disorders psychiatrist whose work has helped shape the clinical evidence base and consensus guidance for ketamine in depression.
Michael Grunebaum
Associate Professor of Psychiatry at Columbia University Irving Medical Center; Research Psychiatrist at the New York State Psychiatric Institute
He is a leading ketamine and suicidality researcher whose clinical trials and meta-analytic work helped shape rapid-acting antidepressant research in psychiatry.
Erwin Krediet
Psychologist and psychedelic researcher at ARQ National Psychotrauma Centre; PhD researcher at Leiden University Medical Center
He is a Dutch psychedelic researcher contributing to clinical studies and educational work on psychedelics, including MDMA-assisted psychotherapy for PTSD and LSD/psilocybin studies.
David Olson
TBD
TBD
Peter Hendricks
Professor of Health Behaviour and Psychedelic Research
Noted for rigorous population‑level epidemiological analyses elucidating associations between classic psychedelic use and mental and physical health outcomes, and for advancing research on microdosing and adverse psychological responses.
Connected Evidence
The latest clinical data and verified academic findings associated with Immunology & Inflammation.